GlassScriptPhysician profile
Casey A Jones
NPI 1255023073
$7,262.03
in general payments reported to CMS, 2019-2025
23 companies · $3,270 in 2025
The $3,270 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,240 · 2024: $2,751 · 2025: $3,270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,074 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,074.03 |
| Education | $188.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,472.19 | 2023-2025 | Tavneos, Evenity, Krystexxa |
| Abbvie INC. | $1,426.76 | 2023-2025 | |
| Janssen Biotech, INC. | $1,003.92 | 2023-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $858.26 | 2024-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $569.25 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $284.10 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $281.20 | 2023-2025 | Saphnelo |
| Lilly USA, LLC | $255.89 | 2023-2024 | Taltz |
| Aurinia Pharma U.S., INC. | $221.82 | 2024-2025 | Lupkynis |
| Organon LLC | $141.43 | 2023-2025 | Hadlima |
| Ani Pharmaceuticals, INC. | $111.15 | 2024-2025 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $108.75 | 2023-2025 | Strensiq |
| Octapharma USA, INC. | $105.00 | 2024-2025 | Octagam Immune Globulin (Human) |
| E.R. Squibb & Sons, L.L.C. | $97.45 | 2024-2025 | Orencia |
| Fresenius Kabi USA, LLC | $86.77 | 2023-2024 | Idacio, Tyenne |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $66.85 | 2025 | Benlysta |
| Procept Biorobotics Corporation | $41.23 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.55 | 2024-2025 | Cyltezo, Ofev |
| Celltrion USA INC. | $26.68 | 2025 | Vegzelma |
| Genentech USA, INC. | $18.59 | 2025 | Actemra |
| Horizon Therapeutics Plc | $17.44 | 2023 | Krystexxa |
| Janssen Scientific Affairs, LLC | $17.19 | 2023 | |
| Tersera Therapeutics LLC | $13.56 | 2023 | Quzyttir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.